Abstract

BackgroundSynucleinopathies comprise a group of neurodegenerative diseases associated with abnormal accumulation of α-synuclein. One of the key factors that contribute to the progression of synucleinopathies is neuroinflammation. However, the role of lymphocytes in synucleinopathies like Parkinson’s disease (PD) remains largely unclear.MethodsTo investigate how lymphocytes impact synucleinopathies, human wild-type α-synuclein (WTS) transgenic mice were crossed with mice lacking mature lymphocytes (Rag2−/−). In this in vivo model, we quantified α-synuclein aggregation in the substantia nigra (SN) and striatum and determined the numbers of innate and adaptive immune cells in the central nervous system (CNS). The activation state of resident and infiltrated CNS myeloid cells (M1 vs. M2) was further classified by gene and protein expression analyses. The impact of T and B lymphocytes on the phagocytic activity of microglia in the presence of α-synuclein aggregates was addressed in BV2 microglia in vitro.ResultsCompared to WTS+ Rag2+/+ mice, where T but not B lymphocytes infiltrated the CNS, decreased amounts of α-synuclein aggregates were found in WTS+ Rag2−/− mice devoid of mature lymphocytes. The presence of T lymphocytes did not alter the number of Iba1+ microglia but increased the frequency of the CD11b+ CD45hi population in the CNS, indicative of an increased number of infiltrated macrophages. Moreover, the M1 phenotype was more prominent in WTS+ Rag2+/+ mice, whereas the M2 activation state was dominating in the absence of lymphocytes in WTS+ Rag2−/− mice. In vitro, in the presence of T but not B lymphocytes, significantly less α-synuclein was phagocytosed by BV2 microglia, further supporting the prevalence of the M1 phenotype in the presence of T lymphocytes.ConclusionsPeripheral T lymphocytes strongly contribute to increased α-synuclein pathology via modulation of CNS myeloid cell function. In the presence of T lymphocytes, microglia phagocytosis of aggregated α-synuclein is reduced, which increases the severity of synucleinopathy.Electronic supplementary materialThe online version of this article (doi:10.1186/s12974-016-0632-5) contains supplementary material, which is available to authorized users.

Highlights

  • Synucleinopathies comprise a group of neurodegenerative diseases associated with abnormal accumulation of α-synuclein

  • We addressed the role of adaptive immune cells in synucleinopathies

  • A more detailed analysis of the adaptive immune cells in wild-type α-synuclein (WTS)+ recombination activating gene 2 (Rag2)+/+ mice revealed that CD3+ T but not CD19+ B lymphocytes infiltrated the midbrain of these mice, suggesting that T lymphocytes influence αsynuclein pathology

Read more

Summary

Introduction

Synucleinopathies comprise a group of neurodegenerative diseases associated with abnormal accumulation of α-synuclein. Synucleinopathies comprise a group of neurodegenerative diseases characterized by abnormal deposition of α-synuclein in neurons and glia. Sommer et al Journal of Neuroinflammation (2016) 13:174 myeloid populations are present including microglia and macrophages (in further termed CNS myeloid cells) [5]. Activated CNS myeloid cells are further divided into classical activation (M1 phenotype), characterized by expression of pro-inflammatory genes (e.g., TNF-α, IL-1β, and ICAM), or alternative activation (M2 phenotype), indicating an anti-inflammatory phagocytic phenotype, expressing characteristic phagocytic and anti-inflammatory genes (e.g., Arg, Lgals, and CD200r), analogous to peripheral myeloid cells. In PD, activated microglia and pro-inflammatory cytokine production were evident in human post mortem brains and animal models [13,14,15,16], the modulation of myeloid cell activation in PD is not yet fully understood

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call